Skip to main content
BeiGene, Ltd. (HKG:6160)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
159.60
-7.10 (-4.26%)
Mar 3, 2025, 4:08 PM HKT

BeiGene Revenue

In the year 2024, BeiGene had annual revenue of $3.81B USD with 54.96% growth. BeiGene had revenue of $1.19B in the quarter ending December 31, 2024, with 84.84% growth.

Revenue
$3.81B
Revenue Growth
+54.96%
P/S Ratio
n/a
Revenue / Employee
$359.46K
Employees
10,600
Market Cap
226.66B HKD

Revenue Chart

* This company reports financials in USD.

History

Fiscal Year End Revenue Change Growth
Dec 31, 20243.81B1.35B54.96%
Dec 31, 20232.46B1.04B73.65%
Dec 31, 20221.42B239.64M20.37%
Dec 31, 20211.18B867.41M280.83%
Dec 31, 2020308.87M-119.34M-27.87%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
JD Health International 58.84B
Hansoh Pharmaceutical Group Company 13.00B
WuXi Biologics 18.39B
Alibaba Health Information Technology 31.39B
Innovent Biologics 8.01B
Akeso 2.01B
Sinopharm Group 634.32B
Sino Biopharmaceutical 29.86B
Revenue Rankings

BeiGene News

More News